Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | March 31, 2021 | April 02, 2021 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | May 13, 2024 | May 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 31, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 26,648.481 |
Reported balance
After 2021-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-31 · Grant · Acquired 554.412 · Balance 26,648.481 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date May 13, 2024 · Filed May 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,802 |
Ending reported balance
After 2024-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-05-13 · Grant · Acquired 559 · Balance 32,408 F1: The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Row 2 · 2024-05-13 · Grant · Acquired 394 · Balance 32,802 F2: The grant was made in lieu of director service fees for the term commencing May 8, 2024. The restricted stock units vest upon the earlier of 5/13/2025, or the business day prior to the Company's next annual meeting of shareholders. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $228.41 · Expires 2034-05-13 | Direct | 1,311 |
Reported balance
After 2024-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-13 · Grant · Acquired 1,311 · Balance 1,311 F3: The stock options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders.
F2: The grant was made in lieu of director service fees for the term commencing May 8, 2024. The restricted stock units vest upon the earlier of 5/13/2025, or the business day prior to the Company's next annual meeting of shareholders.
F3: The stock options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Merck & Co., Inc.
Report date November 03, 2009 · Filed November 04, 2009
Section 16 reporting ended · disclosed 2009-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 1
1 source rowRow 1 · 2009-11-03 · Disposition to issuer · Disposed 104,616 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. |
| Common SharesSEC Table I · non-derivative | IndirectBy 401(k) | 0 |
Reported balance
After 2009-11-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2009-11-03 · Disposition to issuer · Disposed 6,099.41 · Balance 0 F2: In connection with the Merger, each share held in the Issuer's stock fund of the Issuer's 401(k) plan was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Both the shares and cash will remain in the plan until such time as the reporting person elects a distribution therefrom. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.23 · Expires 2013-05-18 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2009-11-03 · Disposition to issuer · Disposed 240,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.87 · Expires 2013-11-16 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2009-11-03 · Disposition to issuer · Disposed 350,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2014-02-22 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2009-11-03 · Disposition to issuer · Disposed 250,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.57 · Expires 2014-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2009-11-03 · Disposition to issuer · Disposed 345,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.70 · Expires 2015-04-24 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2009-11-03 · Disposition to issuer · Disposed 250,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2015-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2009-11-03 · Disposition to issuer · Disposed 260,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2016-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2009-11-03 · Disposition to issuer · Disposed 264,600 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Phantom Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2009-11-03 · Disposition to issuer · Disposed 65,587.15 · Balance 0 F5: Each unit of phantom stock is the economic equivalent of one share of common stock. F6: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.
F2: In connection with the Merger, each share held in the Issuer's stock fund of the Issuer's 401(k) plan was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Both the shares and cash will remain in the plan until such time as the reporting person elects a distribution therefrom.
F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F5: Each unit of phantom stock is the economic equivalent of one share of common stock.
F6: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $134.16 | $13,416.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 29 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,436 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $134.11 | $13,411.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 28 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,536 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $134.10 | $13,410.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 27 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,636 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $134.06 | $13,406.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 26 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,736 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $134.05 | $26,810.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 25 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,836 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $134.04 | $13,404.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 24 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,036 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $134.03 | $13,403.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 23 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,136 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $134.00 | $40,200.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 22 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,236 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $133.99 | $13,399.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 21 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,536 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $133.98 | $13,398.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 20 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,636 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2 | $133.95 | $267.90 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 19 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,736 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2 | $133.94 | $267.88 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 18 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,738 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 102 | $133.93 | $13,660.86 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 17 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,740 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2 | $133.92 | $267.84 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 16 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,842 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $133.91 | $13,391.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 15 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,844 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 202 | $133.90 | $27,047.80 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 14 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,944 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3 | $133.89 | $401.67 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 13 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,146 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 103 | $133.88 | $13,789.64 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 12 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,149 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 224 | $133.87 | $29,986.88 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 11 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,252 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $133.81 | $13,381.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 10 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,476 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $133.68 | $13,368.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 9 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,576 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $133.63 | $13,363.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 8 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,676 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $133.61 | $13,361.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 7 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,776 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $133.46 | $53,384.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 6 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,876 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $133.45 | $13,345.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 5 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,276 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $133.28 | $26,656.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 4 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,376 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $133.21 | $26,642.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 3 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,576 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $133.16 | $13,316.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 2 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,776 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 4,540 | $33.93 | $154,042.20 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2018 Filed Oct 3, 2018 01:42 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 533.586 | $62.08 | $33,125.02 |
DisclosureSEC source: 0000014272-18-000186 · wf-form4_153853090872970.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,331.501 Underlying: Common Stock, $0.10 par value · 533.586 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2018 Filed Jul 4, 2018 01:28 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 583.411 | $55.34 | $32,285.96 |
DisclosureSEC source: 0000014272-18-000151 · wf-form4_153066768153525.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,797.915 Underlying: Common Stock, $0.10 par value · 583.411 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| May 14, 2018 Filed May 15, 2018 18:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 746 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017493 · form4.xml · nonDerivative · entry 2 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,336 F2 · kind: This grant was made in lieu of director service fees for the term commencing May 8, 2018. The restricted stock units vest upon the earlier of 5/14/2019 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 14, 2018 Filed May 15, 2018 18:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017493 · form4.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,590 F1 · kind: Consists of 2,004 unvested restricted stock units that vest upon the earlier of 5/14/2019, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 20:35 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 484.19 | $63.25 | $30,625.02 |
DisclosureSEC source: 0000014272-18-000100 · wf-form4_152278771185646.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,152.612 Underlying: Common Stock, $0.10 par value · 484.19 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,945.86 | $62.80 | $185,000.01 |
DisclosureSEC source: 0000014272-18-000048 · wf-form4_151787286911356.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,668.422 Underlying: Common Stock, $0.10 par value · 2,945.86 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.55 | $11,055.00 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 23 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,586 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.50 | $11,050.00 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 22 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,686 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.43 | $11,043.00 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 21 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,786 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.42 | $11,041.50 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 20 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,886 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 9 | $110.41 | $993.69 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 19 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,986 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 91 | $110.39 | $10,045.49 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 18 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,995 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.39 | $11,038.50 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 17 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,086 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $110.37 | $22,074.00 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 16 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,186 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.36 | $11,036.00 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 15 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,386 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.35 | $11,035.00 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 14 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,486 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.30 | $11,030.00 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 13 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,586 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.28 | $11,028.00 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 12 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,686 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 30 | $110.22 | $3,306.60 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 11 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,786 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $110.19 | $55,095.00 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 10 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,816 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 279 | $110.16 | $30,734.64 |
DisclosureSEC source: 0001127602-18-000591 · form4.xml · nonDerivative · entry 9 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,316 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.